Clinical Trials
6 trialsNCT05512481 2025-03-03
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05051865 2022-11-17
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04979585 2021-08-03
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
The First Hospital of Jilin University
Phase 2 Unknown
NCT04593485 2020-12-23
Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
Fudan University
Phase 2 Unknown
NCT04397770 2020-05-21
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03955354 2019-05-20
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown